

IFW  
Attorney's Docket No.: 14184-051US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : CALI, Brian M., et al

Art Unit : Unknown

Serial No. : 10/575,939 ✓

Examiner : Unknown

Filed : April 13, 2006

Conf. No. : 7082

Title : SELECTIVE COX-2 INHIBITORS

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 8 Feb 2007

  
Anita L. Meiklejohn, Ph.D.  
Reg. No. 35,283

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21554460.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 9, 2007  
Date of Deposit

Carrie A. Amonte  
Signature

Carrie A. Amonte  
Typed or Printed Name of Person Signing Certificate


 Substitute Form PTO-1449  
 (Modified)

 U.S. Department of Commerce  
 Patent and Trademark Office

 Attorney's Docket No.  
 14184-051US1

 Application No.  
 10/575,939

**Information Disclosure Statement  
 by Applicant**

(Use several sheets if necessary)

 Applicant  
 Brian Cali et al.

 Filing Date  
 April 13, 2006

Group Art Unit

(37 CFR § 1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,629,284	12/21/1971	Yamamoto	260	326.13	
	AB	5,684,034	11/4/1997	Bach et al.	514	419	
	AC	5,990,150	11/23/1999	Matsui et al.	514	415	
	AD	6,252,084	6/26/2001	Bach et al.	548	113	
	AE	6,262,098	7/17/2001	Huebner et al.	514	378	
	AF	6,291,505	9/18/2001	Huebner et al.	514	406	
	AG						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AH	WO 00/51685	9/8/2000	WIPO				
	AI	WO 01/06537	1/25/2001	WIPO				
	AJ	WO 03/066046	8/14/2003	WIPO				
	AK	EP1170594	1/9/2002	EPO				
	AL	EP0620214	3/3/1999	EPO				
	AM	UK2407318	4/27/2005	UK				


**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AN	Black et al., "From Indomethacin to a Selective Cox-2 Inhibitor: Development of Indolalkanoic Acids..." Bioorg. & Med. Chem Letters 6(6):725-730, 1996.
	AO	Cravatt et al., "Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System" Curr. Opin. In Chem Biol. 7:469-475, 2003.
	AP	Deutsch et al., "The Fatty Acid Amide Hydrolase (FAAH)" Prostaglandins, Leukotrienes & Essential Fatty Acids 66(2&3):201-210, 2002.
	AQ	Duggan et al., "The Metabolism of Indomethacin in Man" J. of Pharmacol. & Exper. Ther. 181(3):563-575, 1972.
	AR	Fride et al., "Pharmacological Activity of the Cannabinoid Receptor Agonist, Anandamide, a Brain Constituent" Eur. J. of Pharmacol. 231:313-314, 1993.
	AS	Harman et al., "The Metabolites of Indomethacin, A New Anti-Inflammatory Drug" J. of Pharmacol. & Exper. Ther. 143:215-220, 1964.
	AT	Helleberg, L., "Clinical Pharmacokinetics of Indomethacin" Clin. Pharm. 6:245-258, 1981.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


 Substitute Form PTO-1449  
 (Modified)

 U.S. Department of Commerce  
 Patent and Trademark Office

 Attorney's Docket No.  
 14184-051US1

 Application No.  
 10/575,939

**Information Disclosure Statement  
 by Applicant**

(Use several sheets if necessary)

CFR §1.98(b))

 Applicant  
 Brian Cali et al.

 Filing Date  
 April 13, 2006

Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AU	Lau et al., "From Indomethacin to a Selective Cox-2 Inhibitor" Advances in Exper. Med. And Biol. 407:73-78, 1997.
	AV	Maguire et al., "Synthesis of Indomethacin Analogues for Evaluation as Modulators of MRP Activity" Bioorg. & Med. Chem. 9:745-762, 2001.
	AW	Shen et al., "Chemical and Biological Studies on Indomethacin, Sulindac and their Analogs" Adv. In Drug Res. 12:89-245, 1977.
	AX	Shen et al., "Non-Steroid Anti-Inflammatory Agents" J. Am. Chem. Soc. 85(4):488-489, 1963.
	AY	Strachan et al., "Synthesis of Indomethacin Metabolites" J. Med. Chem. 7(6):799-800, 1964.
	AZ	Thomsen et al., "Use of Nitrile Oxides in Synthesis. Novel Synthesis of..." Acta Chemica Scandinavia B42(5):303-308, abstract only.
	AAA	Touhey et al., "Structure-activity Relationship of Indomethacin Analogues for MRP-1, COX-1 and COX-2 Inhibition: ..." Eur. J. of Cancer 38:1661-1670, 2002.
	ABB	Weber et al., "Formation of Prostanoids from Anandamide in FAAH Knockout Mice Analyzed by HPLC..." J. of Lipid Res. 45:757-763, 2004.
	ACC	Walker et al., "Pain Modulation by Release of the Endogenous Cannabinoid Anandamide" PNAS 96(21):12198-12203, 1999.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	